Quantum BioPharma Ltd. (QNTM) develops drug candidates for challenging conditions involving the brain and nervous system, along with metabolic disorders and alcohol misuse. In my view, the main reason investors track the company is its lead program in multiple sclerosis, a condition with still-limited disease-modifying options. Headquartered in Toronto, the firm was previously known as FSD Pharma Inc. and lists its shares on the Nasdaq Capital Market.
The company rebranded from FSD Pharma Inc. to better reflect its biopharmaceutical emphasis. It remains incorporated under Canadian law with headquarters in Toronto, Ontario. Shares trade on Nasdaq under QNTM, as well as on the Canadian Securities Exchange and the Frankfurt Stock Exchange. When I reviewed the competitive landscape, I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Lucid-MS (or Lucid-21-302) sits at the core of the pipeline. This patented compound is designed to prevent and reverse myelin degradation in preclinical models of multiple sclerosis. The company has moved it into a Phase 2 randomized, double-blind, placebo-controlled trial for progressive forms of the disease after receiving FDA clearance for its IND application. Beyond that, Quantum BioPharma created the unbuzzd brand for alcohol misuse and spun out the over-the-counter version to Unbuzzd Wellness Inc., retaining an equity stake and royalty rights while keeping full rights to pharmaceutical formulations.
The business runs through two segments. The Biopharmaceutical Innovation segment handles R&D for candidates like Lucid-MS and medical applications of the unbuzzd technology. The Strategic Investments segment, via subsidiary FSD Strategic Investments Inc., issues loans secured by residential and commercial property to generate returns. As a clinical-stage biotech, the company currently produces no product revenue and shows recurring net losses, which is typical at this stage.
Interest in QNTM centers on Lucid-MS advancing through trials, particularly given the sizable unmet need in progressive multiple sclerosis. A collaboration with the clinical research arm of TMO (Thermo Fisher Scientific) marks an important step. The retained stake in Unbuzzd Wellness and the strategic lending activities add secondary value drivers and some diversification compared with pure-play biotechs.
Investing in QNTM involves the usual risks for clinical-stage biotechs. Development is costly and uncertain, and Lucid-MS could fail to show safety or efficacy or secure approval. Being pre-revenue with ongoing losses, the company may need to raise more capital, potentially diluting shareholders. A dual-class share structure concentrates voting power with Class A multiple voting shares. The lending segment carries real-estate and credit exposure, while digital-asset holdings can add balance-sheet volatility. Valuations in this space often react sharply to regulatory updates, trial data, and broader sentiment toward early-stage healthcare names.
In my own analysis, I frequently rely on Tickeron’s AI Screener to scan for stocks and ETFs based on technical indicators, fundamentals, volatility, trends, and AI signals. It helps me efficiently review names in biotechnology and healthcare, including clinical-stage companies like QNTM, and build watchlists that match specific strategies.
Quantum BioPharma Ltd. (QNTM) is a Toronto-based clinical-stage biopharmaceutical company whose story revolves around Lucid-MS in Phase 2 for progressive multiple sclerosis, supported by an equity interest in the unbuzzd brand and a strategic lending segment. Its place in the neurodegenerative space and diversified structure set it apart in the small-cap biotech arena. As with similar companies, long-term outcomes will hinge on clinical results and the ability to secure necessary funding.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where QNTM advanced for three days, in 198 of 233 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
QNTM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on QNTM as a result. In 55 of 65 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for QNTM turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 34 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
The 10-day moving average for QNTM crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 74%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QNTM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for QNTM entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.142) is normal, around the industry mean (3.586). P/E Ratio (-0.469) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. QNTM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QNTM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company, which engages in the production and processing of hydroponic indoor cannabis.
Industry Biotechnology